Stéphane Bancel, Moderna CEO (Adam Glanzman/Bloomberg via Getty Images)

Mod­er­na says Covid-19 boost­ers stand a fight­ing chance against new vari­ants

A day be­fore its sec­ond an­nu­al Vac­cines Day, Mod­er­na has post­ed an up­date on its crown jew­el, in­clud­ing a 6-month look at the Covid-19 shot and new pre­clin­i­cal da­ta that sug­gest its boost­er can­di­dates stand a fight­ing chance against new vari­ants.

Mod­er­na’s vari­ant-spe­cif­ic boost­er mR­NA-1273.351, which was de­signed to tar­get the B.1.351 mu­ta­tion first iden­ti­fied in South Africa, “closed the neu­tral­iz­ing titer gap for vari­ants of con­cern” in mice, the com­pa­ny said on Tues­day af­ter­noon. When giv­en at the 6-month mark, the boost­er elicit­ed neu­tral­iz­ing titers against the vari­ant that were com­pa­ra­ble to those pro­duced against the orig­i­nal virus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.